Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022136417> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2022136417 abstract "Background: Sustained blood level with effective therapeutic blood level inpsychotic patients in the range of usual therapeutic dose is favorable.Objectives: To investigate where this sustained and effective therapeutic blood level and improve in bioavailability could be achieved by usinghaloperidol/transdermal gel formulation.Materials and Methods: In-vivo transdermal delivery of haloperidol wasstudied in rabbits comparing transdermal gel formulation containing 1, 8-cineole as penetration enhancer and oral tablet. Concentrations of haloperidol in plasma were measured by reverse phase HPLC. The pharmacokinetic parameters generated from this study were evaluatedstatistically using one-way analysis of variance (ANOVA).Result: The results showed that transdermal gel formulation increased rate and extent of absorption and improve bioavailability of haloperidol. The plasma concentrations of haloperidol were declined in biexponential fashion where the area under the curves and absorption rate Cmax/AUC elimination rate constant Kel, Tmax, mean residence time (MRT), mean absorption time (MAT), and total clearance (CLtotal) were significantly different p < 0.05, but volume of distribution (Vd) did not differ significantly p >0.05.The absolute bioavailability from the oral tablet, and the transdermal formulation was 38% and 57% respectively and highly significant P < 0.01.Conclusion: This study suggest that it is possible to achieve significant sustained therapeutic blood levels for longer time and also suggest that further human investigations of the transdermal dosage are warranted.Key words: Haloperidol/Transdermal gel formulation, Oral tablet, Rabbits, Bioavailability,Pharmacokinetic." @default.
- W2022136417 created "2016-06-24" @default.
- W2022136417 creator A5072418109 @default.
- W2022136417 date "2009-08-06" @default.
- W2022136417 modified "2023-09-30" @default.
- W2022136417 title "Bioavailability and In-vivo Transdermal Delivery of Haloperidol" @default.
- W2022136417 cites W155332746 @default.
- W2022136417 cites W1573344022 @default.
- W2022136417 cites W1977540243 @default.
- W2022136417 cites W1986185948 @default.
- W2022136417 cites W2014405952 @default.
- W2022136417 cites W2018038125 @default.
- W2022136417 cites W2040756709 @default.
- W2022136417 cites W2057324815 @default.
- W2022136417 cites W2059545303 @default.
- W2022136417 cites W2119869146 @default.
- W2022136417 cites W2277026843 @default.
- W2022136417 cites W306015106 @default.
- W2022136417 cites W2004367469 @default.
- W2022136417 cites W4183193 @default.
- W2022136417 doi "https://doi.org/10.4314/sjms.v4i1.44875" @default.
- W2022136417 hasPublicationYear "2009" @default.
- W2022136417 type Work @default.
- W2022136417 sameAs 2022136417 @default.
- W2022136417 citedByCount "0" @default.
- W2022136417 crossrefType "journal-article" @default.
- W2022136417 hasAuthorship W2022136417A5072418109 @default.
- W2022136417 hasBestOaLocation W20221364171 @default.
- W2022136417 hasConcept C112705442 @default.
- W2022136417 hasConcept C125287762 @default.
- W2022136417 hasConcept C126322002 @default.
- W2022136417 hasConcept C139254425 @default.
- W2022136417 hasConcept C150903083 @default.
- W2022136417 hasConcept C159985019 @default.
- W2022136417 hasConcept C181389837 @default.
- W2022136417 hasConcept C192562407 @default.
- W2022136417 hasConcept C205679159 @default.
- W2022136417 hasConcept C207001950 @default.
- W2022136417 hasConcept C22979827 @default.
- W2022136417 hasConcept C2775842315 @default.
- W2022136417 hasConcept C2780948584 @default.
- W2022136417 hasConcept C513476851 @default.
- W2022136417 hasConcept C71924100 @default.
- W2022136417 hasConcept C86803240 @default.
- W2022136417 hasConcept C98274493 @default.
- W2022136417 hasConceptScore W2022136417C112705442 @default.
- W2022136417 hasConceptScore W2022136417C125287762 @default.
- W2022136417 hasConceptScore W2022136417C126322002 @default.
- W2022136417 hasConceptScore W2022136417C139254425 @default.
- W2022136417 hasConceptScore W2022136417C150903083 @default.
- W2022136417 hasConceptScore W2022136417C159985019 @default.
- W2022136417 hasConceptScore W2022136417C181389837 @default.
- W2022136417 hasConceptScore W2022136417C192562407 @default.
- W2022136417 hasConceptScore W2022136417C205679159 @default.
- W2022136417 hasConceptScore W2022136417C207001950 @default.
- W2022136417 hasConceptScore W2022136417C22979827 @default.
- W2022136417 hasConceptScore W2022136417C2775842315 @default.
- W2022136417 hasConceptScore W2022136417C2780948584 @default.
- W2022136417 hasConceptScore W2022136417C513476851 @default.
- W2022136417 hasConceptScore W2022136417C71924100 @default.
- W2022136417 hasConceptScore W2022136417C86803240 @default.
- W2022136417 hasConceptScore W2022136417C98274493 @default.
- W2022136417 hasIssue "1" @default.
- W2022136417 hasLocation W20221364171 @default.
- W2022136417 hasOpenAccess W2022136417 @default.
- W2022136417 hasPrimaryLocation W20221364171 @default.
- W2022136417 hasRelatedWork W2010339083 @default.
- W2022136417 hasRelatedWork W2022136417 @default.
- W2022136417 hasRelatedWork W2023029780 @default.
- W2022136417 hasRelatedWork W2026309482 @default.
- W2022136417 hasRelatedWork W2028112905 @default.
- W2022136417 hasRelatedWork W2049802977 @default.
- W2022136417 hasRelatedWork W2056949414 @default.
- W2022136417 hasRelatedWork W2351351947 @default.
- W2022136417 hasRelatedWork W2371846262 @default.
- W2022136417 hasRelatedWork W2373237830 @default.
- W2022136417 hasVolume "4" @default.
- W2022136417 isParatext "false" @default.
- W2022136417 isRetracted "false" @default.
- W2022136417 magId "2022136417" @default.
- W2022136417 workType "article" @default.